Unknown

Dataset Information

0

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients.


ABSTRACT: Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch.

SUBMITTER: van Lierop Z 

PROVIDER: S-EPMC8175839 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8013024 | biostudies-literature
| S-EPMC8597184 | biostudies-literature
| S-EPMC8279996 | biostudies-literature
| S-EPMC4299884 | biostudies-other
| S-EPMC3967702 | biostudies-literature
| S-EPMC10751352 | biostudies-literature
| S-EPMC3537666 | biostudies-literature
| S-EPMC6469695 | biostudies-literature
| S-EPMC4036714 | biostudies-literature
| S-EPMC10769988 | biostudies-literature